Processa Pharmaceuticals, Inc. (PCSA) Stock Price & Analysis
Processa Pharmaceuticals, Inc. (PCSA) — MoonshotScore 27/100 (Weak band), calculated Oct 4, 2026. Price $1.61 (-0.62%), as of the Oct 2, 2026 trading session; market cap $4.46M.
Educational signal · not a buy or sell recommendation · How to read this
Processa Pharmaceuticals, Inc. · PCSA
Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic agents for critical unmet medical needs across dermatology, GI disorders, and oncology. The company is advancing a diverse pipeline of investigational drugs through various clinical trial phases.
Price as of Oct 2, 2026
Key Statistics
MoonshotScore v2 · Processa Pharmaceuticals (PCSA)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet and an expensive valuation, though growth is only middling, and the price trend has turned against it. Business Quality: Thin; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Flat; Momentum: Slipping.
- EPS beat 2 of 8
Holding back: weak fundamentals, balance-sheet strain, a rich price, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 28 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 27 | Weak | |
| 27 | Weak |
The score was 27 in the stored Oct 3, 2026 snapshot and remains 27 in the current publication computed Oct 4, 2026 (0); the largest pillar moves were Momentum -1; the pillar moves offset under the sector-relative weighting, so the headline score is unchanged.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.61 | |
| Change on the day | -0.62% | |
| 52-week range | $1.66 – $14.25 | |
| Market capitalisation | $4.46M | |
| Shares traded on the day | 14.4K |
Price & events
Council Score · weighted blend of 2 available disciplines
Council score for Processa Pharmaceuticals (PCSA): Split View
38/100 · DSome lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 5, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Aug 31, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Dalio-style lens and Klarman-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Aug 31, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 5, 2026, except a card that shows its own read date.
Watch the PCSA film — every key number, told as a short cinematic story
~2 min · open the film
What is Processa Pharmaceuticals (PCSA), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Processa Pharmaceuticals, Inc. (PCSA) is the company analyzed here. It employs 12 people and is led by George K. Ng. The market values it at $4.46M.
What do the latest results show for Processa Pharmaceuticals (PCSA)?
Short answer · as of
Against analyst estimates the company has EPS beat 2 of 8 reports.
What are the financial strengths and risks for Processa Pharmaceuticals (PCSA)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Piotroski F 1. Trailing ratios: current ratio 0.87.
Data-derived red flags
- Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
What should you watch next at Processa Pharmaceuticals (PCSA)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $10.01M · EPS -6.00 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for PCSA.
Checked against the records this page reads, on the dates shown above.
How does Processa Pharmaceuticals compare with its peers?
Short answer
Processa Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $17.03 Sep 23, 2026 | $883M | 95 5-pillar Oct 4, 2026 | |
| $7.19 Oct 2, 2026 | $564M | 94 5-pillar Oct 4, 2026 | |
| $47.15 Oct 2, 2026 | $872M | 93 5-pillar Oct 4, 2026 | |
| $9.99 Oct 2, 2026 | $591M | 91 5-pillar Oct 4, 2026 | |
| $4.59 Oct 2, 2026 | $669M | 88 5-pillar Oct 4, 2026 | |
| $4.45 Oct 2, 2026 | $879M | 85 5-pillar Oct 4, 2026 | |
| $17.08 Oct 2, 2026 | $90.6M | 83 5-pillar Oct 4, 2026 | |
| $9.75 Oct 2, 2026 | $88.2M | 79 5-pillar Oct 4, 2026 | |
| $9.75 Oct 2, 2026 | $690M | 77 5-pillar Oct 4, 2026 | |
| $4.49 Oct 2, 2026 | $184M | 76 5-pillar Oct 4, 2026 | |
| $2.79 Oct 2, 2026 | $222M | 69 5-pillar Oct 4, 2026 | |
| $10.94 Oct 2, 2026 | $626M | 68 5-pillar Oct 4, 2026 | |
| Processa Pharmaceuticals (PCSA) — this page | $1.61 | $4.46M | 27 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $10.01M
- EPS estimate
- $-6.00
Measured against a quoted price of $1.61 (as of Oct 2, 2026).
Insider activity
Form 4 records via FMP · Available records within the last 180 days, newest dated Aug 8, 2026 (coverage not recorded)
- Transactions
- 54
- Identified insiders
- 11
- Purchases
- 34
- Sales
- 0
- Other transactions
- 20
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
What has been published about Processa Pharmaceuticals (PCSA)?
What Investors Ask About Processa Pharmaceuticals (PCSA)
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for PCSA?
PCSA carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is PCSA a good stock to buy?
Stock Expert AI does not rate PCSA buy, sell or hold. Processa Pharmaceuticals, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the PCSA stock price today?
The last price recorded on this page for Processa Pharmaceuticals, Inc. (PCSA) is $1.61, as of the Oct 2, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What are the key factors to evaluate for PCSA?
Processa Pharmaceuticals, Inc. (PCSA) holds a MoonshotScore in the low range. Dividend Policy: Processa Pharmaceuticals does not currently issue dividends, consistent with its clinical-stage profile and reinvestment of capital into pipeline development. Not financial advice.
How frequently does PCSA data refresh on this page?
PCSA's price is the last quote we recorded, from the Oct 2, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven PCSA's recent stock price performance?
Processa Pharmaceuticals, Inc. (PCSA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse clinical-stage pipeline targeting multiple therapeutic areas with unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PCSA overvalued or undervalued right now?
Processa Pharmaceuticals, Inc. (PCSA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PCSA before investing?
Before investing in Processa Pharmaceuticals, Inc. (PCSA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding PCSA to a portfolio?
Key strength of Processa Pharmaceuticals, Inc. (PCSA): Diverse clinical-stage pipeline targeting multiple therapeutic areas with unmet medical needs. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (17 figures)
The 17 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
FMP — 6 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
px.last | Latest provided price | $1.61 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-05T03:54:30.404Z. | |
px.change | Change on the day | -0.62% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $4.46M | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-02. FMP quote timestamp: 2026-10-02T20:00:00.000Z. Captured from FMP at 2026-10-05T03:54:28.475Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$0.01 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 14.4K | FMP | Financial Modeling Prep (FMP) · quote | |
own.insiders | Insider transactions via FMP | 54 transactions · 34 purchases, 0 sales, 20 other transactions · 11 identified insiders · available records within the last 180 days, newest dated Aug 8, 2026 (coverage not recorded) | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. |
UNRECORDED — 9 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 2 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-09-03 · Expired observation | |
px.range52 | 52-week range | $1.66 – $14.25 | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
id.employees | Employees | 12 | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
id.ceo | Chief executive | George K. Ng | UNRECORDED | Stored company-profile observation — Captured 2026-09-30 | |
fin.scores | Distress and quality screens | Piotroski F 1 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-04 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | current ratio 0.87 | — | UNRECORDED | Stored key metrics — Date unknown |
earn.estimates | Analyst estimates, next fiscal year | FY2026 revenue $10.01M · EPS -6.00 · 1 analysts | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation | |
earn.est_revenue | Revenue estimate, FY2026 | $10.01M | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation | |
earn.est_eps | EPS estimate, FY2026 | $-6.00 | UNRECORDED | Stored analyst estimates — Captured 2026-06-16 · Expired observation |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 27 of 100 · Weak · pillars 24 / 16 / 0 / 44 / 20 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 27 (stored snapshot Oct 3, 2026) → 27 (current publication computed Oct 4, 2026) (0) | OURS | Stock Expert AI current score publication and immutable score snapshots |
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Data provided for informational purposes only.